REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 янв 2024 08:45:04 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 янв 2024 08:50:53 Источник NetDania Notify

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 янв 2024 06:00:41 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 янв 2024 08:47:16 Источник NetDania Notify

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25 янв 2024 13:29:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 янв 2024 08:45:06 Источник NetDania Notify

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

24 янв 2024 11:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

24 янв 2024 08:45:06 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 янв 2024 08:45:08 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

22 янв 2024 13:22:25 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

17 янв 2024 08:45:04 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 янв 2024 09:01:13 Источник NetDania Notify

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 янв 2024 08:45:02 Источник NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 дек 2023 15:05:00 Источник Nasdaq GlobeNewswire

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 дек 2023 18:30:00 Источник Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 дек 2023 11:30:00 Источник Nasdaq GlobeNewswire

Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

07 дек 2023 06:00:45 Источник Nasdaq GlobeNewswire